LABELS · de3ee3bd-0047-4365-a4c7-5786521a1649

ENBREL

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-05-11
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SERIOUS INFECTIONS and MALIGNANCIES WARNING: SERIOUS INFECTIONS and MALIGNANCIES See full prescribing information for complete boxed warning. SERIOUS INFECTIONS Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. ( 5.1 ) Enbrel should be discontinued if a patient develops a serious infection or sepsis during treatment. ( 5.1 ) Perform test for latent TB; if positive, start treatment for TB prior to starting Enbrel. ( 5.1 ) Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, including Enbrel. ( 5.3 ) SERIOUS INFECTIONS Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Enbrel should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before Enbrel use and during therapy. Initiate treatment for latent infection prior to Enbrel use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, including Enbrel.

Indications and usage: exact source text

1 INDICATIONS AND USAGE Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 ) Pediatric patients with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 years of age or older ( 1.5 ) 1.1 Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. 1.2 Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.3 Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate. 1.4 Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). 1.5 Plaque Psoriasis Enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. 1.6 Juvenile Psoriatic Arthritis Enbrel is indicated for the treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and older.

Full extracted label fields

application numbers

BLA103795

boxed warning exact

WARNING: SERIOUS INFECTIONS and MALIGNANCIES WARNING: SERIOUS INFECTIONS and MALIGNANCIES See full prescribing information for complete boxed warning. SERIOUS INFECTIONS Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. ( 5.1 ) Enbrel should be discontinued if a patient develops a serious infection or sepsis during treatment. ( 5.1 ) Perform test for latent TB; if positive, start treatment for TB prior to starting Enbrel. ( 5.1 ) Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, including Enbrel. ( 5.3 ) SERIOUS INFECTIONS Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Enbrel should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before Enbrel use and during therapy. Initiate treatment for latent infection prior to Enbrel use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, including Enbrel.

brand names

ENBREL

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a002b40c-097d-47a5-957f-7a7b1807af7f

generic names

ETANERCEPT

de3ee3bd-0047-4365-a4c7-5786521a1649

indications and usage exact

1 INDICATIONS AND USAGE Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 ) Pediatric patients with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 years of age or older ( 1.5 ) 1.1 Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. 1.2 Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.3 Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate. 1.4 Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). 1.5 Plaque Psoriasis Enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. 1.6 Juvenile Psoriatic Arthritis Enbrel is indicated for the treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and older.

indications and usage tables exact

is original packager

true

manufacturer names

Immunex Corporation

matched search terms

tumor

package ndcs

58406-425-41
58406-425-34
58406-424-01
58406-910-01
58406-021-01
58406-021-04
58406-021-96
58406-032-01
58406-032-04
58406-032-96
58406-032-90
58406-010-01

product ndcs

58406-010
58406-425
58406-021
58406-032
58406-044
58406-055

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Indications and Usage, Juvenile Psoriatic Arthritis ( 1.6 ) 10/2023 Dosage and Administration, Pediatric Patients ( 2.4 ) 10/2023

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

253014
261105
727757
802652
809158
809159
1653223
1653225
2182338
2182340
2392140
2392142

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA103795

brand names

ENBREL

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 459
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 ) Pediatric patients with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 y
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 0

current approval status

not_reconciled

duplicate text group

dup-32b3dd7737d9c7b5efec

extraction review status

automated_candidate_pending_source_review

generic names

ETANERCEPT

ind-span-19f6aef4fa39112fe83e

label id

de3ee3bd-0047-4365-a4c7-5786521a1649

positive predicate support span

end: 81
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 31

qualifier mentions

context exact
crosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis
kind
age
polarity
not_inferred
span
end
118
end exclusive
true
exact text
Adult patients
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
104

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 259
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 )
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22de3ee3bd-0047-4365-a4c7-5786521a1649%22

spl effective date

2026-05-11

spl set id

a002b40c-097d-47a5-957f-7a7b1807af7f

spl version

218

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

BLA103795

brand names

ENBREL

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 687
end exclusive: true
exact text: NF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 ) Pediatric patients with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 years of age or older ( 1.5 ) 1.1 Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in pat
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 60

current approval status

not_reconciled

duplicate text group

dup-b48e831524a393487717

extraction review status

automated_candidate_pending_source_review

generic names

ETANERCEPT

ind-span-a784bb24709ad225f06b

label id

de3ee3bd-0047-4365-a4c7-5786521a1649

positive predicate support span

end: 81
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 31

qualifier mentions

context exact
Pediatric patients with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2
kind
age
polarity
not_inferred
span
end
278
end exclusive
true
exact text
Pediatric patients
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
260
context exact
s with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of a
kind
age
polarity
not_inferred
span
end
351
end exclusive
true
exact text
2 years of age
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
337
context exact
years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 years of age or
kind
age
polarity
not_inferred
span
end
413
end exclusive
true
exact text
2 years of age
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
399
context exact
s, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 years of age or older ( 1.5 )
kind
age
polarity
not_inferred
span
end
470
end exclusive
true
exact text
4 years of age
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
456

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 487
end exclusive: true
exact text: Pediatric patients with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 years of age or older ( 1.5 )
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 260

source url

https://api.fda.gov/drug/label.json?search=id%3A%22de3ee3bd-0047-4365-a4c7-5786521a1649%22

spl effective date

2026-05-11

spl set id

a002b40c-097d-47a5-957f-7a7b1807af7f

spl version

218

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 3 · positive indication candidate

application numbers

BLA103795

brand names

ENBREL

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 954
end exclusive: true
exact text: yarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 years of age or older ( 1.5 ) 1.1 Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. 1.2 Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to seve
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 288

current approval status

not_reconciled

duplicate text group

dup-3b69605e7f9ed59a1772

extraction review status

automated_candidate_pending_source_review

generic names

ETANERCEPT

ind-span-b4f3b416bef242efa3b3

label id

de3ee3bd-0047-4365-a4c7-5786521a1649

positive predicate support span

end: 532
end exclusive: true
exact text: is indicated
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 520

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 754
end exclusive: true
exact text: 1.1 Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA).
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 488

source url

https://api.fda.gov/drug/label.json?search=id%3A%22de3ee3bd-0047-4365-a4c7-5786521a1649%22

spl effective date

2026-05-11

spl set id

a002b40c-097d-47a5-957f-7a7b1807af7f

spl version

218

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 4 · unclassified context

application numbers

BLA103795

brand names

ENBREL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1032
end exclusive: true
exact text: symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. 1.2 Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 y
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 555

current approval status

not_reconciled

duplicate text group

dup-274d31103f5ac066d054

extraction review status

automated_candidate_pending_source_review

generic names

ETANERCEPT

ind-span-6d3ca07b1a54fbc0b1ee

label id

de3ee3bd-0047-4365-a4c7-5786521a1649

positive predicate support span

Source null

qualifier mentions

context exact
Enbrel can be initiated in combination with methotrexate (MTX) or used alone.
kind
biomarker
polarity
not_inferred
span
end
831
end exclusive
true
exact text
methotrexate (MTX) or used alone
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
799
context exact
Enbrel can be initiated in combination with methotrexate (MTX) or used alone.
kind
regimen
polarity
not_inferred
span
end
831
end exclusive
true
exact text
in combination with methotrexate (MTX) or used alone
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
779

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 832
end exclusive: true
exact text: Enbrel can be initiated in combination with methotrexate (MTX) or used alone.
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 755

source url

https://api.fda.gov/drug/label.json?search=id%3A%22de3ee3bd-0047-4365-a4c7-5786521a1649%22

spl effective date

2026-05-11

spl set id

a002b40c-097d-47a5-957f-7a7b1807af7f

spl version

218

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · positive indication candidate

application numbers

BLA103795

brand names

ENBREL

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1254
end exclusive: true
exact text: uctural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. 1.2 Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.3 Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients wit
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 633

current approval status

not_reconciled

duplicate text group

dup-abe3103cb3e7e8a97c09

extraction review status

automated_candidate_pending_source_review

generic names

ETANERCEPT

ind-span-aecfeaaf82f98cd5e768

label id

de3ee3bd-0047-4365-a4c7-5786521a1649

positive predicate support span

end: 900
end exclusive: true
exact text: is indicated
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 888

qualifier mentions

context exact
yarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
1043
end exclusive
true
exact text
2 years of age
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
1029

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1054
end exclusive: true
exact text: 1.2 Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 833

source url

https://api.fda.gov/drug/label.json?search=id%3A%22de3ee3bd-0047-4365-a4c7-5786521a1649%22

spl effective date

2026-05-11

spl set id

a002b40c-097d-47a5-957f-7a7b1807af7f

spl version

218

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 6 · positive indication candidate

application numbers

BLA103795

brand names

ENBREL

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1482
end exclusive: true
exact text: nile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.3 Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate. 1.4 Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). 1.5 Plaque Psorias
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 855

current approval status

not_reconciled

duplicate text group

dup-28eddf7adb1d98f003ba

extraction review status

automated_candidate_pending_source_review

generic names

ETANERCEPT

ind-span-507a4935a9b7d501653e

label id

de3ee3bd-0047-4365-a4c7-5786521a1649

positive predicate support span

end: 1098
end exclusive: true
exact text: is indicated
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1086

qualifier mentions

context exact
age of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA).
kind
age
polarity
not_inferred
span
end
1250
end exclusive
true
exact text
adult patients
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
1236

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1282
end exclusive: true
exact text: 1.3 Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA).
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1055

source url

https://api.fda.gov/drug/label.json?search=id%3A%22de3ee3bd-0047-4365-a4c7-5786521a1649%22

spl effective date

2026-05-11

spl set id

a002b40c-097d-47a5-957f-7a7b1807af7f

spl version

218

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

BLA103795

brand names

ENBREL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1531
end exclusive: true
exact text: el is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate. 1.4 Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). 1.5 Plaque Psoriasis Enbrel is indicated for the treatment of patie
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1083

current approval status

not_reconciled

duplicate text group

dup-51c30b683556923665b3

extraction review status

automated_candidate_pending_source_review

generic names

ETANERCEPT

ind-span-c700265c6b376a59642c

label id

de3ee3bd-0047-4365-a4c7-5786521a1649

positive predicate support span

Source null

qualifier mentions

context exact
Enbrel can be used with or without methotrexate.
kind
biomarker
polarity
not_inferred
span
end
1330
end exclusive
true
exact text
methotrexate
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
1318
context exact
Enbrel can be used with or without methotrexate.
kind
regimen
polarity
not_inferred
span
end
1330
end exclusive
true
exact text
with or without methotrexate
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
1302

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1331
end exclusive: true
exact text: Enbrel can be used with or without methotrexate.
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1283

source url

https://api.fda.gov/drug/label.json?search=id%3A%22de3ee3bd-0047-4365-a4c7-5786521a1649%22

spl effective date

2026-05-11

spl set id

a002b40c-097d-47a5-957f-7a7b1807af7f

spl version

218

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA103795

brand names

ENBREL

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1663
end exclusive: true
exact text: inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate. 1.4 Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). 1.5 Plaque Psoriasis Enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1132

current approval status

not_reconciled

duplicate text group

dup-f1e224cafd1d24e1c205

extraction review status

automated_candidate_pending_source_review

generic names

ETANERCEPT

ind-span-b3b41e89f58521324926

label id

de3ee3bd-0047-4365-a4c7-5786521a1649

positive predicate support span

end: 1378
end exclusive: true
exact text: is indicated
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1366

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1463
end exclusive: true
exact text: 1.4 Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1332

source url

https://api.fda.gov/drug/label.json?search=id%3A%22de3ee3bd-0047-4365-a4c7-5786521a1649%22

spl effective date

2026-05-11

spl set id

a002b40c-097d-47a5-957f-7a7b1807af7f

spl version

218

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 9 · positive indication candidate

application numbers

BLA103795

brand names

ENBREL

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1828
end exclusive: true
exact text: c arthritis (PsA). Enbrel can be used with or without methotrexate. 1.4 Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). 1.5 Plaque Psoriasis Enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. 1.6 Juvenile Psoriatic Arthritis Enbrel is indicated for the treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and older.
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1264

current approval status

not_reconciled

duplicate text group

dup-399b5426c326c70befae

extraction review status

automated_candidate_pending_source_review

generic names

ETANERCEPT

ind-span-c4099a7b4cb5cd5261a6

label id

de3ee3bd-0047-4365-a4c7-5786521a1649

positive predicate support span

end: 1504
end exclusive: true
exact text: is indicated
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1492

qualifier mentions

context exact
Psoriasis Enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (
kind
age
polarity
not_inferred
span
end
1542
end exclusive
true
exact text
4 years
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
1535

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1663
end exclusive: true
exact text: 1.5 Plaque Psoriasis Enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1464

source url

https://api.fda.gov/drug/label.json?search=id%3A%22de3ee3bd-0047-4365-a4c7-5786521a1649%22

spl effective date

2026-05-11

spl set id

a002b40c-097d-47a5-957f-7a7b1807af7f

spl version

218

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · positive indication candidate

application numbers

BLA103795

brand names

ENBREL

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1828
end exclusive: true
exact text: 1.5 Plaque Psoriasis Enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. 1.6 Juvenile Psoriatic Arthritis Enbrel is indicated for the treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and older.
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1464

current approval status

not_reconciled

duplicate text group

dup-f07f03b13ba3b4fbab96

extraction review status

automated_candidate_pending_source_review

generic names

ETANERCEPT

ind-span-4c1199bbb0cf94a8d115

label id

de3ee3bd-0047-4365-a4c7-5786521a1649

positive predicate support span

end: 1716
end exclusive: true
exact text: is indicated
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1704

qualifier mentions

context exact
treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
1802
end exclusive
true
exact text
pediatric patients
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
1784
context exact
e juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
1817
end exclusive
true
exact text
2 years of age
label id
de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start
1803

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1828
end exclusive: true
exact text: 1.6 Juvenile Psoriatic Arthritis Enbrel is indicated for the treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and older.
label id: de3ee3bd-0047-4365-a4c7-5786521a1649
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9beed0eef1b24a5de08ae1830acb43ec324d83830206c89fde54ca021a4a211e
start: 1664

source url

https://api.fda.gov/drug/label.json?search=id%3A%22de3ee3bd-0047-4365-a4c7-5786521a1649%22

spl effective date

2026-05-11

spl set id

a002b40c-097d-47a5-957f-7a7b1807af7f

spl version

218

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice